



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Thursday, 18 September 2025

10:00 – 12:00

Scientific Business Meetings

13:00 – 13:55

Session I: Current EBMT recommendations

Chairs: Tobias Alexander (DE) & Donal McLornan (UK)

13:00 – 13:15

EBMT recommendations for HCT in MDS

Carmelo Gurnari (IT)

13:15 – 13:30

EBMT recommendations for HCT in autoimmune diseases

Elisa Roldan Galvan (UK)

13:30 – 13:45

EBMT recommendations for CART in autoimmune diseases

Raffaella Greco (IT)

13:45 – 13:55

Panel discussion

13:55 – 15:00

Session II: MDS diagnosis and prognosis

Chairs: Kavita Raj (UK) & Adriano Venditti (IT)

13:55 – 14:10

MDS in 2025: a molecular era of diagnostic and prognostic classifiers

Mario Cazzola (IT)

14:10 – 14:25

HCT or not in MDS? How to decide with current prognostic scoring systems

Nico Gagelmann (DE)

14:25 – 14:40

Are we ready for AI to help in the management of MDS?

Adrian Mosquera (ES)

14:40 – 14:50

Case presentation

14:50 – 15:00

Panel discussion

15:00 – 15:30

Coffee break

15:30 – 16:50

Session III: MDS treatment

Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)

15:30 – 15:45

Current treatment algorithm in Lower-risk MDS

Maria Teresa Voso (IT)

15:45 – 16:00

Current treatment algorithm in Higher-risk MDS and the AML/MDS border

Amer Zeidan (US)

16:00 – 16:15

Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint

Jaroslav Maciejewski (US)

16:15 – 16:30

Access to genomics and transplant policies in MDS in Latin-America

Gonzalo Bentolila (AR)

16:30 – 16:40

Case presentation

16:40 – 16:50

Panel discussion

16:50 – 17:20

Coffee break

17:20 – 18:30

Session IV: Autoinflammation in haematology and beyond

Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)

17:20 – 17:35

VEXAS: the lynchpin between inflammation and myeloid neoplasia

Carmelo Gurnari (IT)

17:35 – 17:50

CMML and autoimmune/inflammatory conditions

Francesco Onida (IT)

17:50 – 18:05

Incidence and management of HLH in autoimmune diseases

Coralie Bloch (FR)

18:05 – 18:15

Case presentation

18:15 – 18:30

Panel discussion

For further information, please contact education.events@ebmt.org

Friday, 19 September 2025

09:00 – 10:10

Joint Physician-Nurse session HCT in MDS in 2025

Chairs: *Maike de Ruijter (NL) & William Arcese (IT)*

09:00 – 09:15

Which donor to choose in the PtCy era?

09:15 – 09:30

Bridging or not prior to allo-HCT for MDS?

09:30 – 09:45

Conditioning regimens in the contemporary era

09:45 – 10:00

Issues on maintenance and management of relapse

10:00 – 10:15

Panel discussion

Kavita Raj (UK)

Nicolaus Kröger (DE)

Joanna Drozd-Sokolowska (PL)

Marie Robin (FR)

10:15 – 11:00

Industry Symposium

11:00 – 11:30

Coffee break

11:30 – 12:50

Session V: HCT in autoinflammation and autoimmunity

Chairs: *John Snowden (UK) & Andrea Bacigalupo (IT)*

11:30 – 11:45

HCT in VEXAS

11:45 – 12:00

HCT in Behçet's disease

12:00 – 12:15

HCT in systemic sclerosis

12:15 – 12:30

HCT for AID in Brazil: Current Practices

12:30 – 12:40

Case presentation

12:40 – 12:50

Panel discussion

Donal McLornan (UK)

Mathieu Puyade (FR)

Nicoletta del Papa (IT)

Fernando Barroso Duarte (BR)

12:50 – 14:00

Lunch break

14:00 – 15:20

Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases

Chairs: *Patrizia Chiusolo (IT) & Paolo Muraro (UK)*

14:00 – 14:15

Novel treatment approaches in myeloma

14:15 – 14:30

Bispecifics in myeloma: bridging to CAR-T?

14:30 – 14:45

Bone marrow plasma cell landscape in health and disease

14:45 – 15:00

Plasma cell depletion in autoimmune diseases

15:00 – 15:10

Case presentation

15:10 – 15:20

Panel discussion

Elisa Roldan Galvan (UK)

Patrick Hayden (IE)

Farzin Mashreghi (DE)

Tobias Alexander (DE)

15:20 – 15:50

Coffee break

15:50 – 17:15

Session VII: Novel cellular therapies in autoimmune diseases

Chairs: *Simona Sica (IT) & Dominique Farge (FR)*

15:50 – 16:05

Bispecific antibodies in rheumatoid arthritis

16:05 – 16:20

CART in rheumatoid arthritis

16:20 – 16:35

CAR-T cell therapies in pediatric autoimmune diseases

16:35 – 16:50

iPS cells for tissue regeneration in autoimmune disease

16:50 – 17:00

Case presentation

17:00 – 17:15

Panel discussion

Ricardo Grieshaber (DE)

Doron Rimar (IS)

Marco Becilli (IT)

Richard Burt (US)



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Saturday, 20 September 2025

08:45 – 09:45 **Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases**

Chairs: *Claudia Boggione (IT) & Basil Sharrack (UK)*

08:45 – 09:00 Autologous HCT in MS

09:00 – 09:15 CAR T in MS

09:15 – 09:30 Cellular therapies in other neurologic indications

09:30 – 09:45 Panel discussion

Alice Mariottini (IT)

Lena Kristina Pfeffer (DE)

Aiden Haghikia (DE)

10:00 – 10:45 **Industry Symposium**

10:45 – 11:30 **Poster Tour**

11:30 – 12:50 **Session VIII: Immune monitoring post CART and late complications for autoimmune disease**

Chairs: *Franco Locatelli (IT) & Raffaella Greco (IT)*

11:30 – 11:45 Immune monitoring post-CART

11:45 – 12:00 Late complications in HCT

12:00 – 12:15 Late complications in CART

12:15 – 12:30 Secondary HLH after CART

12:30 – 12:40 *Case presentation*

12:40 – 12:50 Panel discussion

Simona Pagliuca (FR)

Kirill Krigizov (RU)

Maeve O'Reilly (UK)

Matteo Doglio (IT)

12:50 – 13:00 **Take-home messages from all the organizers**